New Drug Delivery Systems Market: Market Size & Forecast 2026

The drug delivery systems market covers a wide spectrum of technologies enabling controlled, targeted, and efficient administration of pharmaceutical compounds, ranging from conventional devices to advanced electronic and smart systems. Multiple industry analyses converge on a market valuation in the range of roughly $245 billion to $277 billion in 2024, with projections placing it near $311.9 billion in 2026 and continuing upward. Key product categories include auto-injectors and other electronic delivery devices, as well as established forms such as inhalation systems, transdermal patches, and conventional and advanced injectable systems, distributed through hospital pharmacies, retail pharmacies, and specialty channels.

• •Market estimated between $245 billion and $277 billion in 2024 across various report segments, rising to approximately $311.9 billion in 2026
• •Growth driven across all delivery segments with injectable systems representing the largest revenue category, followed by inhalation and transdermal systems
• •Injectable drug delivery segment specifically projected to grow from $690 billion in 2025 to over $1,000 billion by 2030 at an 8.4% CAGR, outpacing the broader market

The expanding pipeline of biologic drugs, peptide therapeutics, and biosimilars fundamentally requires delivery systems capable of handling molecules that are incompatible with conventional oral formulations, creating sustained structural demand. Rising global prevalence of chronic conditions such as diabetes, autoimmune disorders, and cardiovascular disease drives ongoing volume growth in self-administered therapies that patients manage outside hospital environments. Patient adherence benefits from connected and electronic delivery devices, which offer features such as dose tracking and automated injection, aligning with healthcare systems' broader push toward decentralized care and reduced clinical burden.

• •Biologic drug proliferation and biosimilar entry consistently expand the addressable market for parenteral and advanced delivery technologies
• •Chronic disease burden and aging demographics sustain long-term demand across all major delivery categories
• •Self-administration and home-based care trends reduce reliance on clinical settings, supporting growth in patient-friendly electronic and auto-injector platforms

Product segmentation broadly distinguishes electronic drug delivery systems, including auto-injectors and connected injection devices, from conventional systems across oral, transdermal, inhalation, and other modalities, with injectable-based delivery dominating overall market share. Device-level segmentation separates conventional delivery apparatus from advanced systems incorporating electronics, connectivity, and enhanced usability features, with the advanced category growing at an accelerated pace. Geographically, North America represents the largest regional market, supported by established pharmaceutical infrastructure, high healthcare spending, and regulatory frameworks that favor device innovation, while Asia-Pacific emerges as the fastest-growing region as local manufacturing and healthcare access expand.

• •Injectable delivery systems command the largest share, with electronic and auto-injector sub-segments expanding rapidly
• •North America holds the dominant regional position, with Europe and Asia-Pacific following; Asia-Pacific is the fastest-growing region
• •Hospital pharmacies remain the primary distribution channel, though retail and specialty pharmacy channels gain share with the shift toward outpatient self-administration

Who are the notable companies in the industry?

The global Novel Drug Delivery Systems (NDDS) market, projected to reach USD 417.88 billion by 2031, is shaped by a fragmented competitive landscape dominated by diversified healthcare giants with specialized technological focus. Abbott Laboratories leads in next-generation continuous glucose monitoring (CGM) and automated delivery systems, transforming diabetes care through precision patient-centric technologies. Bayer AG and F. Hoffmann-La Roche AG are key innovators in nanocarrier-based delivery, leveraging liposomes and nanoparticles for targeted, molecular-level drug distribution to enhance efficacy and reduce systemic toxicity. GlaxoSmithKline Plc and Merck & Co., Inc. drive advancement across multiple modalities, including transdermal and inhaler systems, aligning with evolving therapeutic demands. Pfizer Inc. stands as a leading player, strategically deploying advanced delivery platforms to optimize pharmacokinetics and patient compliance. Medtronic complements this group with its leadership in implantable and automated delivery technologies, particularly in chronic disease management. These firms cluster around distinct delivery platforms, nanotechnology, injectables, and wearable systems, rather than offering end-to-end solutions, reflecting a market defined by niche innovation. Capacity and R&D hubs remain concentrated in North America and Western Europe, where regulatory expertise and high-value manufacturing converge to support next-generation delivery systems.

• •Market is fragmented with no single producer dominating; competition spans specialized device manufacturers, CDMOs, and diversified healthcare corporations
• •Participants tend to specialize by delivery modality or technology platform rather than offering fully integrated portfolios across all device types
• •High-value R&D and advanced manufacturing capacity concentrated in North America and Europe, with Asia-Pacific growing in contract manufacturing and mid-tier device production

What are the recent trends and outlook?

Connectivity and digital integration represent the most significant technology trend, with drug delivery devices increasingly incorporating sensors, Bluetooth or connected capabilities, and companion applications that enable real-time monitoring and data capture for patients and healthcare providers. Modular and reusable platform designs are gaining traction among manufacturers seeking to reduce development costs and accelerate time-to-market for new drug-device combinations. The market's long-term trajectory remains strongly positive, with the 6.1% CAGR sustained through the near term as demographic tailwinds, biologics pipeline expansion, and digital health convergence continue to reinforce structural demand across all delivery system categories.

• •Connected and smart drug delivery devices integrating digital health features are rapidly becoming a defining competitive and product category differentiator
• •Device modularity and reusable platform architectures are adopted to accelerate drug-device combination development and regulatory approval timelines
• •Market expected to continue expanding at approximately 6% annually through 2030, with injectable and electronic delivery segments leading growth acceleration